Recordati to acquire rights to CAD treatment Enjaymo from Sanofi
Recordati agreed to acquire the global rights to Enjaymo (sutimlimab), the only approved targeted therapy for cold agglutinin disease (CAD), from Sanofi. “With a strong clinical profile and as the only product approved for the treatment of CAD, Enjaymo addresses a serious unmet medical need for patients…